Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis

Cancer

Volumn 107, Issue 12, 2006, Pages 2888-2897

  Maertens, Johan ^a   Glasmacher, Axel ^b   Herbrecht, Raoul ^c   Thiebaut, Anne ^d   Cordonnier, Catherine ^e   Segal, Brahm H ^f   Killar, John ^g   Taylor, Arlene ^g   Kartsonis, Nicholas ^g   Patterson, Thomas F ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF BONN   (Germany)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Aspergillosis; Caspofungin; Combination therapy; Salvage therapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; ITRACONAZOLE; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ACUTE LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CHILL; CHRONIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERNATREMIA; JAUNDICE; LEUKOCYTE COUNT; LIVER TOXICITY; LUNG ASPERGILLOSIS; LUNG TUMOR; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPEN STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; TREATMENT OUTCOME; VOMITING;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RECURRENCE; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 33845574728     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22348     Document Type: Article

References (17)

1. Beck-Sague CM, Jarvis WR, National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 1999;167:1247-1251.
2. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001;33:1692-1696.
3. Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358-366.
4. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917.
5. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus study group. Medicine. 2000;79:250-260.
6. Maertens J, Theunissen K, Boogaerts M. Invasive aspergillosis: focus on new approaches and new therapeutic agents. Curr Med Chem Anti-infective Agents. 2002;1:65-81.
7. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-571.
8. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
9. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563-1571.
10. Millis W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-center experience of 133 episodes in 116 patients. Br J Hematol. 1994;86:754-760.
11. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26:1383-1396.
12. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother. 2002;46:2564-2568.
13. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother. 2002;46:3039-3041.
14. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Inf Dis. 2003;187:1834-1843.
15. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97:1025-1032.
16. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797-802.
17. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.